David Epstein Sells 250 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 250 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.40, for a total value of $12,350.00. Following the transaction, the director owned 31,464 shares in the company, valued at $1,554,321.60. This trade represents a 0.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Up 10.0%

NASDAQ:TEM opened at $52.26 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The stock’s fifty day moving average is $48.90 and its two-hundred day moving average is $57.56. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32. The stock has a market capitalization of $9.38 billion, a price-to-earnings ratio of -30.38 and a beta of 3.62.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. During the same period in the prior year, the firm earned ($0.24) earnings per share. The firm’s revenue was up 36.1% compared to the same quarter last year. Research analysts anticipate that Tempus AI, Inc. will post -1.35 EPS for the current year.

Wall Street Analyst Weigh In

TEM has been the topic of several analyst reports. Stifel Nicolaus set a $60.00 price objective on Tempus AI in a research note on Wednesday, February 25th. Robert W. Baird initiated coverage on Tempus AI in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective on the stock. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Wolfe Research initiated coverage on Tempus AI in a research note on Tuesday. They issued a “peer perform” rating on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $80.00 price objective on shares of Tempus AI in a research note on Monday. Nine analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Tempus AI has a consensus rating of “Hold” and a consensus price target of $68.64.

Hedge Funds Weigh In On Tempus AI

Several large investors have recently bought and sold shares of TEM. JPL Wealth Management LLC purchased a new position in Tempus AI in the third quarter valued at $26,000. Los Angeles Capital Management LLC purchased a new position in Tempus AI in the fourth quarter valued at $27,000. Harvest Fund Management Co. Ltd purchased a new position in Tempus AI in the third quarter valued at $38,000. Whittier Trust Co. increased its holdings in Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after buying an additional 570 shares during the last quarter. Finally, Lodestone Wealth Management LLC purchased a new position in Tempus AI in the fourth quarter valued at $42,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.